Catalym Gmbh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Catalym gmbh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Catalym Gmbh Today - Breaking & Trending Today

SANA : Minutes from the AGM 2024 (unofficial translation)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

. ....

New York , United States , United Kingdom , Annika Bostr , Setterwalls Advokatbyr , Thomas Feldthus , Inrikes Tidningar , Dan Peters , Ola Grahn , Anna Ljung , Pierandrea Muglia , Carl Johan Sundberg , Cecilia Andr , Svenska Dagbladet , John Haurum , Institute Of Molecular Medicine , University Of Oxford , Swedish Companies , Audit Committee , Vp Research At Imclone Systems , Remuneration Committee , Swedish Securities Register Center , Nomination Committee , Swedish Companies Act Sw , Neophore Ltd , Swedish Companies Act ,

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

Catalym Gmb , Phil Lhuillier , Ignacio Melero Center , World Health Organization , International Nonproprietary Name , Trophic Communications , Differentiation Factor , Ignacio Melero , Advanced Medical Research , Principal Investigator , Eugen Leo , Chief Medical Officer , Phill Huillier , Growth Differentiation , Laura Mittmann , Catalym Gmbh , Business Wire ,

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
The poster
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER) , Abstract TPS2658
, will present CatalYm s first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment. In the GDFATHER-trial, patients with advanced-stage, solid tumors who have not responded or stopped responding to anti-PD-1/PD-L1 therapy are treated with CTL-002 as monotherapy and followed by combination with an anti-PD-1 antibody. The first patient was enrolled in December 2020. ....

United States , Christine Schuberth Wagner , Katja Arnold , Wachstumsfonds Bayern , Phil Lhuilier , Shaun Brown , Kostenloser Wertpapierhandel , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , European Union , European Fund For Strategic Investments , Novartis Venture Fund , Distribution Services , Catalym Gmbh , Present Initial Data , First In Human Trial , American Society , Clinical Oncology , Developmental Therapeutics , Eugen Leo , Chief Medical Officer , Chief Scientific Officer , Phill Huillier , Chief Executive Officer ,

CatalYm Appoints Industry Leader Dr. Phil L'Huillier as

MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the. ....

New Zealand , United States , Katja Arnold , Wachstumsfonds Bayern , Artios Pharma , Shaun Brown , John Haurum , Catalym Gmb , Phil Lhuillier , Joerg Wischhusen , Mc Services , Board Member Of Cancer Research Technology , European Fund For Strategic Investments , Merck Co , European Union , University Of Auckland , Novartis Venture Fund , Business Development , Phill Huillier , Chief Executive Officer , European Innovation Hub , North America , Licensing Leadership , Executive Director , Board Member , Cancer Research Technology ,